338 related articles for article (PubMed ID: 34090021)
1. Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm.
Garcia MA; Barreras PV; Lewis A; Pinilla G; Sokoll LJ; Kickler T; Mostafa H; Caturegli M; Moghekar A; Fitzgerald KC; ; Pardo CA
J Neurol Sci; 2021 Aug; 427():117517. PubMed ID: 34090021
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation.
Garcia MA; Barreras PV; Lewis A; Pinilla G; Sokoll LJ; Kickler T; Mostafa H; Caturegli M; Moghekar A; Fitzgerald KC; Pardo CA
medRxiv; 2021 Jan; ():. PubMed ID: 33469596
[TBL] [Abstract][Full Text] [Related]
3. CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome.
Guasp M; Muñoz-Sánchez G; Martínez-Hernández E; Santana D; Carbayo Á; Naranjo L; Bolós U; Framil M; Saiz A; Balasa M; Ruiz-García R; Sánchez-Valle R;
Front Immunol; 2022; 13():866153. PubMed ID: 35479062
[TBL] [Abstract][Full Text] [Related]
4. Fighting the storm: could novel anti-TNFα and anti-IL-6
Kovalchuk A; Wang B; Li D; Rodriguez-Juarez R; Ilnytskyy S; Kovalchuk I; Kovalchuk O
Aging (Albany NY); 2021 Jan; 13(2):1571-1590. PubMed ID: 33465050
[TBL] [Abstract][Full Text] [Related]
5. Myoclonus status revealing COVID 19 infection.
Ben Mohamed D; Zouari R; Ketata J; Nabli F; Blel S; Ben Sassi S
Seizure; 2023 Jan; 104():12-14. PubMed ID: 36446232
[TBL] [Abstract][Full Text] [Related]
6. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses.
Pilotto A; Masciocchi S; Volonghi I; De Giuli V; Caprioli F; Mariotto S; Ferrari S; Bozzetti S; Imarisio A; Risi B; Premi E; Benussi A; Focà E; Castelli F; Zanusso G; Monaco S; Stefanelli P; Gasparotti R; Zekeridou A; McKeon A; Ashton NJ; BlennoW K; Zetterberg H; Padovani A
Clin Infect Dis; 2021 Nov; 73(9):e3019-e3026. PubMed ID: 33395482
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal inflammatory responses in the absence of SARS-CoV-2 nucleic acid in the CSF of COVID-19 hospitalized patients.
Normandin E; Holroyd KB; Collens SI; Shaw BM; Siddle KJ; Adams G; Rudy M; Solomon IH; Anahtar MN; Lemieux JE; Trombetta BA; Kivisakk P; Arnold SE; Rapalino O; Piantadosi AL; Sen P; Rosenberg ES; Branda J; Sabeti PC; Mukerji SS
J Neurol Sci; 2021 Nov; 430():120023. PubMed ID: 34678659
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients.
Jarius S; Pache F; Körtvelyessy P; Jelčić I; Stettner M; Franciotta D; Keller E; Neumann B; Ringelstein M; Senel M; Regeniter A; Kalantzis R; Willms JF; Berthele A; Busch M; Capobianco M; Eisele A; Reichen I; Dersch R; Rauer S; Sandner K; Ayzenberg I; Gross CC; Hegen H; Khalil M; Kleiter I; Lenhard T; Haas J; Aktas O; Angstwurm K; Kleinschnitz C; Lewerenz J; Tumani H; Paul F; Stangel M; Ruprecht K; Wildemann B;
J Neuroinflammation; 2022 Jan; 19(1):19. PubMed ID: 35057809
[TBL] [Abstract][Full Text] [Related]
9. Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children - a cross-sectional observational study from southern India.
Venkataraman A; Kumar NP; Hanna LE; Putlibai S; Karthick M; Rajamanikam A; Sadasivam K; Sundaram B; Babu S
EBioMedicine; 2021 Apr; 66():103317. PubMed ID: 33813138
[TBL] [Abstract][Full Text] [Related]
10. Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms.
Edén A; Grahn A; Bremell D; Aghvanyan A; Bathala P; Fuchs D; Gostner J; Hagberg L; Kanberg N; Kanjananimmanont S; Lindh M; Misaghian S; Nilsson S; Schöll M; Sigal G; Stentoft E; Studahl M; Yilmaz A; Wang M; Stengelin M; Zetterberg H; Gisslén M
JAMA Netw Open; 2022 May; 5(5):e2213253. PubMed ID: 35604688
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid cytokine, chemokine, and SARS-CoV-2 antibody profiles in children with neuropsychiatric symptoms associated with COVID-19.
Ngo B; Lapp SA; Siegel B; Patel V; Hussaini L; Bora S; Philbrook B; Weinschenk K; Wright L; Anderson EJ; Rostad CA; Gombolay GY
Mult Scler Relat Disord; 2021 Oct; 55():103169. PubMed ID: 34333272
[TBL] [Abstract][Full Text] [Related]
12. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
Front Immunol; 2021; 12():700921. PubMed ID: 34539631
[TBL] [Abstract][Full Text] [Related]
13. The brain reacting to COVID-19: analysis of the cerebrospinal fluid proteome, RNA and inflammation.
Reinhold D; Farztdinov V; Yan Y; Meisel C; Sadlowski H; Kühn J; Perschel FH; Endres M; Düzel E; Vielhaber S; Guttek K; Goihl A; Venø M; Teegen B; Stöcker W; Stubbemann P; Kurth F; Sander LE; Ralser M; Otto C; Streit S; Jarius S; Ruprecht K; Radbruch H; Kjems J; Mülleder M; Heppner F; Körtvelyessy P
J Neuroinflammation; 2023 Feb; 20(1):30. PubMed ID: 36759861
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid cytokines in COVID-19: a review and meta-analysis.
Devlin L; Gombolay GY
J Neurol; 2023 Nov; 270(11):5155-5161. PubMed ID: 37581633
[TBL] [Abstract][Full Text] [Related]
15. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
16. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
[TBL] [Abstract][Full Text] [Related]
17. Multisystem inflammatory syndrome in neonates (MIS-N) associated with SARS-CoV2 infection: a case series.
More K; Aiyer S; Goti A; Parikh M; Sheikh S; Patel G; Kallem V; Soni R; Kumar P
Eur J Pediatr; 2022 May; 181(5):1883-1898. PubMed ID: 35031848
[TBL] [Abstract][Full Text] [Related]
18. COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain-Barré syndrome.
Massa F; Vigo T; Bellucci M; Giunti D; Emanuela MM; Visigalli D; Capodivento G; Cerne D; Assini A; Boni S; Rizzi D; Narciso E; Grisanti GS; Coco E; Uccelli A; Schenone A; Franciotta D; Benedetti L
Neurol Sci; 2024 Mar; 45(3):849-859. PubMed ID: 38169013
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development.
Espíndola OM; Brandão CO; Gomes YCP; Siqueira M; Soares CN; Lima MASD; Leite ACCB; Torezani G; Araujo AQC; Silva MTT
Int J Infect Dis; 2021 Jan; 102():155-162. PubMed ID: 33127503
[TBL] [Abstract][Full Text] [Related]
20. An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning β-cell survival and cardiovascular conditions in diabetic patients.
Srivastava A; Rockman-Greenberg C; Sareen N; Lionetti V; Dhingra S
Mol Cell Biochem; 2022 Jun; 477(6):1681-1695. PubMed ID: 35235124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
